Neogap Therapeutics, a biotech company focused on developing personalised cancer immunotherapy, announced today the appointment of Dr. Hanjing Xie as its new Chief Medical Officer (CMO), starting from 21 March.
Dr. Xie will oversee Neogap’s clinical development programs and pipeline and provide medical oversight for the company’s first-in-human study. Dr. Xie is a highly experienced associate professor and senior consultant in oncology with diverse expertise from the pharmaceutical industry and university hospitals.
Neogap Therapeutics recently received CTA approval for phase I/IIa clinical trial with its advanced cell therapy pTTL (personalised Tumour Trained Lymphocytes) cell therapy against colorectal cancer. The phase I/IIa trial is expected to begin in the first half of 2023.
Dr. Hanjing Xie has over 25 years of experience from both the pharmaceutical industry, at companies such as Idogen, Oncopeptides, and Bayer, and from university hospitals and institutes, such as the Karolinska University Hospital, the Karolinska Institute, and St. Göran’s hospital. She is an associate professor and senior consultant in oncology, holds a Ph.D. in clinical pharmacology, and has board certifications in clinical oncology, internal medicine, and hematology.
“We are thrilled to welcome Dr. Hanjing Xie as our new Chief Medical Officer. With extensive experience in research, clinical development, and patient care, Dr. Xie brings a wealth of expertise to Neogap. Her diverse background in the pharmaceutical industry and academia, along with specialised training in clinical oncology, and hematology, make her highly qualified to lead our cell therapy trial,” says Samuel Svensson, CEO of Neogap.
“As someone who has dedicated my career to finding new ways to fight cancer, I’m excited to join Neogap, a company that is at the forefront of personalised cancer immunotherapy. Working together with the experienced team at Neogap, I look forward to advancing innovative science and helping to increase survival rates for cancer patients by enhancing tumor-specific immune responses,” says Dr. Hanjing Xie.
